NCT04196452 2025-11-20
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
Bristol-Myers Squibb
Active not recruiting
Clinical Trials
11 trialsNCT07091695 2025-11-12
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Bristol-Myers Squibb
Completed
NCT07024862 2025-06-17
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
Bristol-Myers Squibb
Active not recruiting
NCT02854488 2022-03-31
Yervoy Pregnancy Surveillance Study
Bristol-Myers Squibb
Withdrawn
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown
NCT04136470 2020-08-10
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
Ardigen
Unknown
NCT04145232 2020-08-10
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
Ardigen
Unknown
NCT04169867 2019-11-20
Polish Microbiome Map
Ardigen
Unknown
NCT03165409 2017-10-05
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
Bristol-Myers Squibb
Completed
NCT02739386 2017-04-27
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases
Bristol-Myers Squibb
Completed
NCT02050594 2015-07-07
Ipilimumab 12-month Intensive Pharmacovigilance Protocol
Bristol-Myers Squibb
Completed